ArticlePloS one2025
Glucocorticoid use and perceptions of side effects among patients with rheumatic medical diseases: Insights from a developing country.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic glucocorticoid (GC) therapy is common in patients with rheumatic medical diseases (RMD). However, long-term use of GCs can be associated with significant adverse effects. This study aims to determine the prevalence of GC use among patients with RMD and understand their perceptions of GC use and safety. This cross-sectional survey was conducted at a tertiary academic university hospital in Amman, Jordan. RMD patients were anonymously approached while awaiting rheumatology clinic appointments. Convenience sampling was employed, with enrollment taking place between January and September 2021. Of 500 participants, 315 (63%) reported current (171/315, 54.3%) or past (144/315, 45.7%) use of GCs, primarily prescribed for RMD (267/315, 84.7%). Most (270/315, 85.7%) used GCs orally, with the majority taking them daily (266/315, 84.4%). A small percentage (33/315, 10.5%) used GCs only as needed. Long-term use was common, with 57.8% (182/315) reporting use for years and 84.1% (265/315) adhering to doctor recommendations. Perception-wise, 69.5% (219/315) of GC users believed in its efficacy, whereas 78.7% (248/315) considered it unsafe, compared to 51.9% (96/185) of non-users. Awareness of side effects was higher among GC users (219/315, 69.5%) than non-users (79/185, 42.7%), with weight gain being the most reported side effect. Media and personal research were the primary information sources for GC users (193/315, 61.3%). Side effects were reported by 110/315 (34.9%) GC users, with weight gain as the most common (47%). Both perceived efficacy and safety of GC were positively and significantly correlated with educational level (p = .005, p = .000, respectively) and monthly income (p = .044, p = .000, respectively). GC use is prevalent among Jordanian patients with RMDs, with perceptions of efficacy and safety strongly influenced by education and income. Enhanced patient education on the side effects of GC is crucial for improving treatment adherence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.